These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 12891224)

  • 41. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.
    Chhun S; Jullien V; Rey E; Dulac O; Chiron C; Pons G
    Epilepsia; 2009 May; 50(5):1150-7. PubMed ID: 19175400
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Age and comedications influence levetiracetam pharmacokinetics in children.
    Dahlin MG; Wide K; Ohman I
    Pediatr Neurol; 2010 Oct; 43(4):231-5. PubMed ID: 20837299
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures.
    Wamil AW; Schmutz M; Portet C; Feldmann KF; McLean MJ
    Eur J Pharmacol; 1994 Dec; 271(2-3):301-8. PubMed ID: 7705430
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phenytoin toxicity secondary to an oxcarbazepine-phenytoin 2C19 interaction.
    Soskin DP; Kane AJ; Stern TA
    Psychosomatics; 2010; 51(6):532-5. PubMed ID: 21051688
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Overnight transition from carbamazepine to oxcarbazepine in children and adolescents.
    Vaisleib II; Neft RA
    Pharmacotherapy; 2008 Oct; 28(10):1211-4. PubMed ID: 18823216
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.
    Lin WW; Li XW; Jiao Z; Zhang J; Rao X; Zeng DY; Lin XH; Wang CL
    Eur J Clin Pharmacol; 2019 Mar; 75(3):381-392. PubMed ID: 30456415
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Central hypothyroidism with oxcarbazepine therapy.
    Miller J; Carney P
    Pediatr Neurol; 2006 Mar; 34(3):242-4. PubMed ID: 16504798
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Severe overdosage with the antiepileptic drug oxcarbazepine.
    van Opstal JM; Janknegt R; Cilissen J; L'Ortije WH; Nel JE; De Heer F
    Br J Clin Pharmacol; 2004 Sep; 58(3):329-31. PubMed ID: 15327594
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers.
    Degen PH; Flesch G; Cardot JM; Czendlik C; Dieterle W
    Biopharm Drug Dispos; 1994 Aug; 15(6):519-26. PubMed ID: 7993989
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment.
    Friis ML; Kristensen O; Boas J; Dalby M; Deth SH; Gram L; Mikkelsen M; Pedersen B; Sabers A; Worm-Petersen J
    Acta Neurol Scand; 1993 Mar; 87(3):224-7. PubMed ID: 8475694
    [TBL] [Abstract][Full Text] [Related]  

  • 51. First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite.
    Dickinson RG; Hooper WD; Dunstan PR; Eadie MJ
    Eur J Clin Pharmacol; 1989; 37(1):69-74. PubMed ID: 2591466
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of plasma and saliva concentrations of the active monohydroxy metabolite of oxcarbazepine in patients at steady state.
    Cardot JM; Degen P; Flesch G; Menge P; Dieterle W
    Biopharm Drug Dispos; 1995 Oct; 16(7):603-14. PubMed ID: 8785383
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oxcarbazepine in the treatment of bipolar and schizoaffective disorders.
    Popova E; Leighton C; Bernabarre A; Bernardo M; Vieta E
    Expert Rev Neurother; 2007 Jun; 7(6):617-26. PubMed ID: 17563245
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetic interactions among phenobarbital, carbamazepine, and valproic acid in pediatric Japanese patients: clinical considerations on steady-state serum concentration-dose ratios.
    Yukawa E; Hokazono T; Satou M; Ohdo S; Higuchi S; Aoyama T
    Am J Ther; 2000 Sep; 7(5):303-8. PubMed ID: 11317175
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials.
    Majid O; Laurenza A; Ferry J; Hussein Z
    Br J Clin Pharmacol; 2016 Aug; 82(2):422-30. PubMed ID: 27038098
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relation of blood platelet count during carbamazepine and oxcarbazepine treatment with daily dose, and serum concentrations of carbamazepine, carbamazepine-10, 11-epoxide, and 10-hydroxycarbazepine.
    Tutor-Crespo MJ; Hermida J; Tutor JC
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2007 Jun; 151(1):91-4. PubMed ID: 17690747
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical profile of oxcarbazepine-related angioneurotic edema: case report and review.
    Knudsen JF; Flowers CM; Kortepeter C; Awaad Y
    Pediatr Neurol; 2007 Aug; 37(2):134-7. PubMed ID: 17675030
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine.
    van Heiningen PN; Eve MD; Oosterhuis B; Jonkman JH; de Bruin H; Hulsman JA; Richens A; Jensen PK
    Clin Pharmacol Ther; 1991 Oct; 50(4):410-9. PubMed ID: 1914377
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oxcarbazepine disposition: preliminary observations in patients.
    Kumps A; Wurth C
    Biopharm Drug Dispos; 1990; 11(4):365-70. PubMed ID: 2340349
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oxcarbazepine: clinical development program.
    Schwabe S
    Epilepsia; 1994; 35 Suppl 5():S51-3. PubMed ID: 8039472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.